Q1 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Alector in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Alector’s Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.66) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.39) EPS.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10. The firm had revenue of $15.34 million for the quarter, compared to analyst estimates of $16.33 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%.

Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research report on Tuesday. Morgan Stanley downgraded Alector from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $10.00 to $3.00 in a report on Tuesday. Finally, BTIG Research decreased their target price on Alector from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, Alector presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Alector Trading Down 1.0 %

Shares of Alector stock opened at $2.55 on Thursday. Alector has a 12-month low of $2.37 and a 12-month high of $8.90. The company has a market cap of $249.24 million, a P/E ratio of -1.50 and a beta of 0.66. The company’s fifty day simple moving average is $4.68 and its two-hundred day simple moving average is $5.00.

Insider Activity

In other news, CEO Arnon Rosenthal sold 26,499 shares of Alector stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the transaction, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at $9,509,880.48. The trade was a 1.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Marc Grasso sold 7,297 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $35,609.36. Following the completion of the transaction, the chief financial officer now owns 130,740 shares in the company, valued at approximately $638,011.20. The trade was a 5.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,722 shares of company stock worth $232,883. Insiders own 9.10% of the company’s stock.

Institutional Investors Weigh In On Alector

A number of institutional investors have recently made changes to their positions in the company. FMR LLC lifted its position in Alector by 1.0% in the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after acquiring an additional 137,794 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alector by 12.0% during the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock valued at $29,574,000 after purchasing an additional 526,037 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Alector by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company’s stock valued at $8,874,000 after buying an additional 148,357 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Alector by 7.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,148,326 shares of the company’s stock worth $5,213,000 after buying an additional 75,481 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Alector by 18.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,017,687 shares of the company’s stock worth $4,742,000 after buying an additional 159,111 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.